ALVR | AlloVir, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	9.01 - 9.69
52 Week Range	7.96 - 24.15
Beta	0.28
Implied Volatility	370.29%
IV Rank	87.78%
Day's Volume	65,226
Average Volume	22,882
Shares Outstanding	5,024,650
Market Cap	47,131,217
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-07-30

Valuation
Profitability
Growth
Health
P/E Ratio	-0.46
Forward P/E Ratio	N/A
EPS	-20.24
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	8
Country	USA
Website	ALVR

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

ALVR's peers: ADCT, ANEB, MLYS, ANTX, AVTE, ADAG, FIXX, STOK, BCEL, BDTX, FDMT, ACRV, CGEM, AGIO, CRNX, INBX, MRUS, LYEL, KRON, ANAB, BYSI, DSGN, INKT, RVSN

*Chart delayed

Analyzing fundamentals for ALVR we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see ALVR Fundamentals page.

Watching at ALVR technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on ALVR Technicals page.